跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 47,906 条关于
“IMPACT Therapeutics”
全部
47,906
临床试验
24,368
药物
3,143
机构
1,141
资讯
19,254
上个月
IMPACT Therapeutics Licenses PARP Inhibitor Senaparib to Pharmanovia in Deal Worth Up to €423.5 Million
去年
Senaparib Approved in China for First-Line Maintenance Therapy in Ovarian Cancer
去年
FDA Rejects Applied Therapeutics' Govorestat for Galactosemia, Citing Clinical Application Deficiencies
昨天
CHMP Backs Senaparib as First-Line Maintenance Therapy in Advanced Ovarian Cancer
去年
Synfini and O2nix Bio Partner to Develop AI-Driven Cancer Metastasis Therapies Targeting FTSJ1
3年前
Iterum Therapeutics Receives U.S. Patent Allowance for Oral Sulopenem Combination Therapy
去年
Leap Therapeutics Reports Mixed Phase II Results for Sirexatamab in Gastrointestinal Cancers
9天前
1cBio Licenses Preclinical PARP1 Inhibitor OC-3 to Lee's Pharm for Greater China and Southeast Asia in Deal Worth Up to $27 Million
去年
Tempest Therapeutics Advances Phase 3 Trial of TPST-1120 Combination for Hepatocellular Carcinoma
去年
Fate Therapeutics Shifts Focus to Autoimmune Diseases with Promising Cell Therapies
第 1 页,共 1926 页
上一页
下一页